Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia
Objective: The aim of the research was to study the effect of azithromycin (AZM) in the treatment of MDR P. aeruginosa VAP combined with other antimicrobial therapies.Methods: The clinical outcomes were retrospectively collected and analyzed to elucidate the efficacy of different combinations involv...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.944965/full |
| _version_ | 1828286839681712128 |
|---|---|
| author | Yuqin Huang Wenguo Wang Qiang Huang Zhengyan Wang Zhuanzhuan Xu Chaochao Tu Dongli Wan Miaobo He Xiaoyi Yang Huaqiang Xu Hanqin Wang Ying Zhao Mingli Tu Quan Zhou |
| author_facet | Yuqin Huang Wenguo Wang Qiang Huang Zhengyan Wang Zhuanzhuan Xu Chaochao Tu Dongli Wan Miaobo He Xiaoyi Yang Huaqiang Xu Hanqin Wang Ying Zhao Mingli Tu Quan Zhou |
| author_sort | Yuqin Huang |
| collection | DOAJ |
| description | Objective: The aim of the research was to study the effect of azithromycin (AZM) in the treatment of MDR P. aeruginosa VAP combined with other antimicrobial therapies.Methods: The clinical outcomes were retrospectively collected and analyzed to elucidate the efficacy of different combinations involving azithromycin in the treatment of MDR-PA VAP. The minimal inhibitory concentration (MIC) of five drugs was measured by the agar dilution method against 27 isolates of MDR-PA, alone or in combination.Results: The incidence of VAP has increased approximately to 10.4% (961/9245) in 5 years and 18.4% (177/961) caused by P. aeruginosa ranking fourth. A total of 151 cases of MDR P. aeruginosa were included in the clinical retrospective study. Clinical efficacy results are as follows: meropenem + azithromycin (MEM + AZM) was 69.2% (9/13), cefoperazone/sulbactam + azithromycin (SCF + AZM) was 60% (6/10), and the combination of three drugs containing AZM was 69.2% (9/13). The curative effect of meropenem + amikacin (MEM + AMK) was better than that of the meropenem + levofloxacin (MEM + LEV) group, p = 0.029 (p < 0.05). The curative effect of cefoperazone/sulbactam + amikacin (SCF + AMK) was better than that of the cefoperazone/sulbactam + levofloxacin (SCF + LEV) group, p = 0.025 (p < 0.05). There was no significant difference between combinations of two or three drugs containing AZM, p > 0.05 (p = 0.806). From the MIC results, the AMK single drug was already very sensitive to the selected strains. When MEM or SCF was combined with AZM, the sensitivity of them to strains can be significantly increased. When combined with MEM and AZM, the MIC50 and MIC90 of MEM decreased to 1 and 2 ug/mL from 8 to 32 ug/mL. When combined with SCF + AZM, the MIC50 of SCF decreased to 16 ug/mL, and the curve shifted obviously. However, for the combination of SCF + LEV + AZM, MIC50 and MIC90 could not achieve substantive changes. From the FIC index results, the main actions of MEM + AZM were additive effects, accounting for 72%; for the combination of SCF + AZM, the additive effect was 40%. The combination of AMK or LEV with AZM mainly showed unrelated effects, and the combination of three drugs could not improve the positive correlation between LEV and AZM.Conclusion: AZM may increase the effect of MEM or SCF against MDR P. aeruginosa VAP. Based on MEM or SCF combined with AMK or AZM, we can achieve a good effect in the treatment of MDR P. aeruginosa VAP. |
| first_indexed | 2024-04-13T09:38:48Z |
| format | Article |
| id | doaj.art-57ad0d7febe0407a965bf9a53a5a6d09 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T09:38:48Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-57ad0d7febe0407a965bf9a53a5a6d092022-12-22T02:52:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-08-011310.3389/fphar.2022.944965944965Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated PneumoniaYuqin Huang0Wenguo Wang1Qiang Huang2Zhengyan Wang3Zhuanzhuan Xu4Chaochao Tu5Dongli Wan6Miaobo He7Xiaoyi Yang8Huaqiang Xu9Hanqin Wang10Ying Zhao11Mingli Tu12Quan Zhou13Intensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Medicine, First Clinical School, Guangzhou Medical University, Guangzhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaCenter for Translational Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaDepartment of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan, ChinaDepartment of Respiratory Medicine, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaIntensive Care Unit, Suizhou Central Hospital, Hubei University of Medicine, Suizhou, ChinaObjective: The aim of the research was to study the effect of azithromycin (AZM) in the treatment of MDR P. aeruginosa VAP combined with other antimicrobial therapies.Methods: The clinical outcomes were retrospectively collected and analyzed to elucidate the efficacy of different combinations involving azithromycin in the treatment of MDR-PA VAP. The minimal inhibitory concentration (MIC) of five drugs was measured by the agar dilution method against 27 isolates of MDR-PA, alone or in combination.Results: The incidence of VAP has increased approximately to 10.4% (961/9245) in 5 years and 18.4% (177/961) caused by P. aeruginosa ranking fourth. A total of 151 cases of MDR P. aeruginosa were included in the clinical retrospective study. Clinical efficacy results are as follows: meropenem + azithromycin (MEM + AZM) was 69.2% (9/13), cefoperazone/sulbactam + azithromycin (SCF + AZM) was 60% (6/10), and the combination of three drugs containing AZM was 69.2% (9/13). The curative effect of meropenem + amikacin (MEM + AMK) was better than that of the meropenem + levofloxacin (MEM + LEV) group, p = 0.029 (p < 0.05). The curative effect of cefoperazone/sulbactam + amikacin (SCF + AMK) was better than that of the cefoperazone/sulbactam + levofloxacin (SCF + LEV) group, p = 0.025 (p < 0.05). There was no significant difference between combinations of two or three drugs containing AZM, p > 0.05 (p = 0.806). From the MIC results, the AMK single drug was already very sensitive to the selected strains. When MEM or SCF was combined with AZM, the sensitivity of them to strains can be significantly increased. When combined with MEM and AZM, the MIC50 and MIC90 of MEM decreased to 1 and 2 ug/mL from 8 to 32 ug/mL. When combined with SCF + AZM, the MIC50 of SCF decreased to 16 ug/mL, and the curve shifted obviously. However, for the combination of SCF + LEV + AZM, MIC50 and MIC90 could not achieve substantive changes. From the FIC index results, the main actions of MEM + AZM were additive effects, accounting for 72%; for the combination of SCF + AZM, the additive effect was 40%. The combination of AMK or LEV with AZM mainly showed unrelated effects, and the combination of three drugs could not improve the positive correlation between LEV and AZM.Conclusion: AZM may increase the effect of MEM or SCF against MDR P. aeruginosa VAP. Based on MEM or SCF combined with AMK or AZM, we can achieve a good effect in the treatment of MDR P. aeruginosa VAP.https://www.frontiersin.org/articles/10.3389/fphar.2022.944965/fullventilator-associated pneumoniaPseudomonas aeruginosaazithromycinin vitro drug sensitivity testmultidrug-resistant |
| spellingShingle | Yuqin Huang Wenguo Wang Qiang Huang Zhengyan Wang Zhuanzhuan Xu Chaochao Tu Dongli Wan Miaobo He Xiaoyi Yang Huaqiang Xu Hanqin Wang Ying Zhao Mingli Tu Quan Zhou Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia Frontiers in Pharmacology ventilator-associated pneumonia Pseudomonas aeruginosa azithromycin in vitro drug sensitivity test multidrug-resistant |
| title | Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia |
| title_full | Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia |
| title_fullStr | Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia |
| title_full_unstemmed | Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia |
| title_short | Clinical Efficacy and In Vitro Drug Sensitivity Test Results of Azithromycin Combined With Other Antimicrobial Therapies in the Treatment of MDR P. aeruginosa Ventilator-Associated Pneumonia |
| title_sort | clinical efficacy and in vitro drug sensitivity test results of azithromycin combined with other antimicrobial therapies in the treatment of mdr p aeruginosa ventilator associated pneumonia |
| topic | ventilator-associated pneumonia Pseudomonas aeruginosa azithromycin in vitro drug sensitivity test multidrug-resistant |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.944965/full |
| work_keys_str_mv | AT yuqinhuang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT wenguowang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT qianghuang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT zhengyanwang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT zhuanzhuanxu clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT chaochaotu clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT dongliwan clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT miaobohe clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT xiaoyiyang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT huaqiangxu clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT hanqinwang clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT yingzhao clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT minglitu clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia AT quanzhou clinicalefficacyandinvitrodrugsensitivitytestresultsofazithromycincombinedwithotherantimicrobialtherapiesinthetreatmentofmdrpaeruginosaventilatorassociatedpneumonia |